ERAS
Erasca IncKey Statistics
About Erasca Inc
Erasca Inc. is an innovative biopharmaceutical company specializing in the development of targeted therapies for genetically defined cancers, addressing significant unmet medical needs within oncology. Leveraging its proprietary drug discovery platform that combines advanced genomics with precision medicine, Erasca focuses on creating therapies aimed at specific mutations that drive cancer progression. The company boasts a robust pipeline of clinical-stage candidates designed to disrupt key tumor growth pathways, enhancing treatment standards in cancer care. Erasca's dedication to improving patient outcomes is bolstered by strategic collaborations within the oncology research community, positioning it as a leader in the field.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-128.30M |
| Operating Margin | 0.00% |
| Return on Equity | -33.30% |
| Return on Assets | -18.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.14 |
| Price-to-Book | 16.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $310.80M |
| Float | $224.17M |
| % Insiders | 10.66% |
| % Institutions | 75.86% |
Historical Volatility
Volatility is currently expanding